Chen Cheng, Wang Jun, Li Jianchuan, Zhang Wanchao, Ou Santao
Department of Clinical Nutrition, The First People's Hospital of Yibin, Yibin, Sichuan, China.
Department of Gastroenterology, The First People's Hospital of Yibin, Yibin, Sichuan, China.
J Ren Nutr. 2023 Jan;33(1):126-139. doi: 10.1053/j.jrn.2022.04.001. Epub 2022 Apr 19.
The current systematic review and meta-analysis investigated the effects of probiotic, prebiotic, and synbiotic administration on inflammation, metabolic parameters, nutritional status, and uremic toxin in dialysis patients.
Up to June 2021, publications were searched in Cochrane Library, PubMed, EMBASE, and Web of Science databases. The protocol was submitted to the International Prospective Register of Systematic Reviews and was approved.
This meta-analysis included 18 randomized controlled trials which were eligible. This meta-analysis discovered that probiotic, prebiotic, and synbiotic supplements could reduce C-reactive protein (standardized mean difference (SMD), -0.38; 95% confidence interval (CI), -0.68 to -0.08; P = .01), interleukin 6 (SMD, -0.48; 95% CI, -0.76 to -0.20; P = .00), and indoxyl sulfate (SMD, -0.24; 95% CI, -0.48 to -0.01; P = .045) and increase high-density lipoprotein cholesterol (SMD, 0.25; 95% CI, 0.03 to 0.46; P = .025) compared with the control group but had no significant influence on tumor necrosis factor α, albumin, hemoglobin, triglyceride, total cholesterol, low-density lipoprotein cholesterol, calcium, phosphorus, uric acid, or p-cresyl sulfate in dialysis patients.
Probiotic, prebiotic, and synbiotic administration could reduce C-reactive protein, interleukin 6, and indoxyl sulfate and increase high-density lipoprotein cholesterol in dialysis patients. To better examine the impact, large-scale, long-term, controlled diets and well-designed randomized controlled trials are needed.
本系统评价和荟萃分析探讨了给予益生菌、益生元及合生元对透析患者炎症、代谢参数、营养状况和尿毒症毒素的影响。
截至2021年6月，在Cochrane图书馆、PubMed、EMBASE和Web of Science数据库中检索相关出版物。该方案已提交至国际前瞻性系统评价注册库并获批准。
该荟萃分析纳入了18项符合条件的随机对照试验。该荟萃分析发现，与对照组相比，补充益生菌、益生元及合生元可降低C反应蛋白（标准化均数差（SMD），-0.38；95%置信区间（CI），-0.68至-0.08；P = 0.01）、白细胞介素6（SMD，-0.48；95% CI，-0.76至-0.20；P = 0.00）和硫酸吲哚酚（SMD，-0.24；95% CI，-0.48至-0.01；P = 0.045），并增加高密度脂蛋白胆固醇（SMD，0.25；95% CI，0.03至0.46；P = 0.025），但对透析患者的肿瘤坏死因子α、白蛋白、血红蛋白、甘油三酯总胆固醇、低密度脂蛋白胆固醇、钙、磷、尿酸或对甲酚硫酸盐无显著影响。
给予益生菌、益生元及合生元可降低透析患者的C反应蛋白、白细胞介素6和硫酸吲哚酚，并增加高密度脂蛋白胆固醇。为了更好地研究其影响，需要大规模、长期的对照饮食和设计良好的随机对照试验。
